CurrentCignaPolicy N/A

Veregen Prior Authorization Policy

Defines prior authorization requirements and medical necessity criteria for topical Veregen (sinecatechins ointment) for treatment of external genital and perianal warts for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyVeregen Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document age (≥18), immunocompetent status, and prior trials of both podofilox and imiquimod.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥18minimum patient age for coverage

4 monthsapproval duration

2 agentsprior therapy required

Other usesnon-covered uses

Coverage Criteria for Veregen (sinecatechins)

FDA-Approved Indication

Covered when ALL of the following are met for the FDA-approved indication:

A: Patient is ≥ 18 years of age;
B: Patient is immunocompetent, according to the prescriber;
C
- i: Podofilox gel or solution has been tried;
- ii:

Policy Summary

PayerCigna

PolicyVeregen Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document age (≥18), immunocompetent status, and prior trials of both podofilox and imiquimod.

SourceLink

On This Page

Coverage for Veregen (sinecatechins ointment) is limited to the FDA‑approved indication for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent adults. The policy does not cover use in immunosuppressed patients, treatment courses that exceed 16 weeks, or multiple treatment courses because safety and efficacy have not been established for those situations. Use for any other unapproved indication is explicitly excluded and considered not medically necessary.

Veregen is considered not medically necessary for any use(s) beyond the stated FDA‑approved indication. This stance will be revised if and when new published evidence becomes available. Providers seeking coverage for off‑label uses should note that requests for non‑approved indications will be denied unless supported by updated clinical evidence and corresponding policy changes.

Provider Responsibilities and Authorization Requirements

Prior Authorization

Prior authorization required — approvals for a set duration

Prior authorization is required for prescription benefit coverage of Veregen; approvals are provided for the duration specified in the policy (approve for 4 months when FDA-approved criteria are met).

Step Therapy

Step therapy — trial of two topical agents required

Patient must have tried BOTH podofilox (gel or solution) AND imiquimod cream before Veregen will be approved for the FDA‑approved indication.

i. Podofilox gel or solution
ii. Imiquimod cream

Documentation Required

Required documentation — age, immunocompetence, prior trials

Document the patient's age (≥ 18 years), that the patient is immunocompetent per the prescriber, and prior trials of both podofilox (gel or solution) and imiquimod cream.

Patient age ≥ 18 years
Prescriber's statement that patient is immunocompetent
Evidence of prior trial of podofilox (gel or solution)
Evidence of prior trial of imiquimod cream

Denial Risk

Denial triggers — missing authorization, criteria, or documentation

Coverage may be denied if prior authorization is not obtained, if the patient does not meet the FDA‑approved indication (including age ≥ 18 and immunocompetent status), or if required prior trials of podofilox and imiquimod are not documented.

No prior authorization obtained
Patient younger than 18 years or not documented as immunocompetent
Missing documentation of prior trials of both podofilox and imiquimod
Use for any non‑FDA‑approved indication

Definitions

External genital and perianal warts — locations and CDC guidance

DefinitionCondylomata acuminata (external genital and perianal warts) located on the penis, groin, scrotum, vulva, perineum, external anus, or perianus.

FDA‑approved indicationTopical treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients ≥ 18 years of age.

Limitations of useSafety and efficacy not established in immunosuppressed patients, for treatment beyond 16 weeks, or for multiple treatment courses.

CDC guidance referenceCDC Sexually Transmitted Diseases Treatment Guidelines list Veregen as a patient‑applied option alongside imiquimod and podofilox and define relevant anogenital locations.

Background

Veregen is a botanical topical ointment indicated for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients ≥ 18 years of age. The manufacturer’s labeled limitations state that safety and efficacy have not been established in immunosuppressed patients, for treatment beyond 16 weeks, or for multiple treatment courses. The agent is one of several patient‑applied options cited in guideline contexts for treating external genital warts.